Chronic total occlusion (CTO) is a complete or nearly complete blockage of one or more coronary arteries. The blockage, typically present for at least three months, is caused by a buildup of plaque within a coronary artery. When this happens, blood flow to the heart is compromised.
Medical Services related to Daniel Stephen Menees MD
Frequently asked questions about TAVR, including the definition, advantages and recovery information.
The MitraClip procedure is used to treat patients who have symptoms because of mitral regurgitation. The MitraClip procedure does not require opening the chest or temporarily stopping your heart (cardiopulmonary bypass). Instead, doctors access your heart through a vein in your leg to repair your mitral valve. The MitraClip procedure may be an option for patients with mitral regurgitation who are too sick for surgery or considered too high risk.
The mitral valve controls the flow of blood going in one direction from the lungs to the body. If the valve does not close properly, or open completely, the heart may have to work twice as hard to do its job, which can lead to life threatening heart conditions. Frankel Cardiovascular Center heart doctors offer advanced mitral valve treatments that can't be found at other hospitals because of U-M's involvement in clinical trials.
Treatment options for mitral valve disease include medication therapy, open-heart surgery, and minimally invasive procedures, both surgical and transcatheter. Performing these repairs early in the disease process before a patient's mitral valve disease progresses into advanced heart conditions such as congestive heart failure, atrial fibrillation, and pulmonary hypertension is our top priority.
TAVR stands for Transcatheter Aortic Valve Replacement, a minimally invasive, catheter-based procedure to replace the diseased aortic valve in patients with severe aortic stenosis. Aortic stenosis is a condition in which the aortic valve does not open fully due to a thickening of the valve leaflets, often caused by a buildup of calcium on the leaflets. This thickening makes it difficult for the leaflets to open and close, which decreases blood flow from the heart to the body. The condition may cause the heart to work harder to pump blood. For decades, open heart surgical aortic valve replacement (SAVR) has been the standard treatment for severe aortic stenosis, but in the past few years TAVR has rapidly replaced SAVR in high-risk patients as well as patients at moderate risk for surgery. This is due to excellent clinical trial results showing equal or better patient outcomes compared to SAVR. Most recently, in August of 2019, TAVR was approved for patients at low risk for surgery. These low-risk patients, whose aortic stenosis would typically receive an open-heart surgical aortic valve replacement, can now be considered a candidate for a TAVR procedure.